Report
Hugo Solvet

QIAGEN: Strong Q1, but low Q2 guidance | BUY | EUR37.5(+9%)

QIAGEN - BUY | EUR37.5(+9%)
Strong Q1, but low Q2 guidance

Strong MDx drove 6.1%CER topline growth in Q1
Operating margin a touch below expectations; slight EPS beat
Low Q2 guidance might trigger profit taking moves…
…despite reiterated FY guidance and new USD100m SBB program
Underlying
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Hugo Solvet

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch